SEPE, PIERANGELA
SEPE, PIERANGELA
Universita' degli Studi di MILANO
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
2022 A. Mennitto, E. Zattarin, M. Di Maio, D. Bimbatti, U. De Giorgi, S. Buti, D. Santini, C. Casadei, M. Soraru, C. Messina, C. Mucciarini, G. Di Lorenzo, G. Roviello, C. Buttigliero, M. Stellato, P. Sepe, M. Claps, V. Guadalupi, A. Ottini, S. Pignata, F.G. De Braud, E. Verzoni, G. Procopio
Biomarker-driven immunotherapy for precision medicine in prostate cancer
2022 A. Ottini, P. Sepe, T. Beninato, M. Claps, V. Guadalupi, E. Verzoni, P. Giannatempo, G. Baciarello, F. De Braud, G. Procopio
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma
2021 R. Ratta, E. Verzoni, A. Mennitto, F. Pantano, A. Martinetti, A. Raimondi, P. Sepe, E. Sottotetti, R. Mennitto, D. Morelli, D. Santini, F. de Braud, G. Procopio
Integrative transcriptomic analysis reveals distinctive molecular traits and novel subtypes of collecting duct carcinoma
2021 C. Gargiuli, P. Sepe, A. Tessari, T. Sheetz, M. Colecchia, F.G.M. de Braud, G. Procopio, M. Sensi, E. Verzoni, M. Dugo
| Titolo | Data di pubblicazione | Autori | Tipo | File | Abstract |
|---|---|---|---|---|---|
| Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) | 2022 | Mennitto A.Zattarin E.Di Lorenzo G.Sepe P.Ottini A.De Braud F. G.Verzoni E. + | Article (author) | - | |
| Biomarker-driven immunotherapy for precision medicine in prostate cancer | 2022 | Ottini A.Sepe P.Beninato T.Verzoni E.Giannatempo P.De Braud F.Procopio G. + | Article (author) | - | |
| Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma | 2021 | P. SepeF. de Braud + | Article (author) | - | |
| Integrative transcriptomic analysis reveals distinctive molecular traits and novel subtypes of collecting duct carcinoma | 2021 | Sepe P.de Braud F. G. M. + | Article (author) | - |